Literature DB >> 10172485

Economic evaluation of drugs and its potential uses in policy making.

M Johannesson1.   

Abstract

Interest in the economic evaluation of drug treatments is steadily increasing, but the impact of such evaluations on decisions concerning the use of drugs is unclear. In this article I examine different decision and policy situations where economic evaluations of drug treatments could potentially be used. Economic evaluations may be used as an aid to the development of treatment guidelines, decisions within healthcare organisations, and decisions relating to approval, reimbursement and pricing. Economic evaluations appear to be most useful in the development of treatment guidelines and as an aid to reimbursement decisions. The incentive to use economic evaluations embodied in the healthcare system is also important. It is argued that it is too early to introduce regulations that require the use economic evaluations in, for example, reimbursement decisions. A more cautious approach might be preferred, where economic evaluations are used more selectively until the methodology and the field have developed further.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10172485     DOI: 10.2165/00019053-199508030-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

1.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

2.  Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.

Authors:  D Henry
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

Review 3.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

4.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

5.  Applying the Australian guidelines for the reimbursement of pharmaceuticals.

Authors:  M Aristides; A Mitchell
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

6.  [Recommendations from an expert group: individualized treatment of hypertension].

Authors: 
Journal:  Lakartidningen       Date:  1990-06-27
  6 in total
  5 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels.

Authors:  Marieke E van Velden; Johan L Severens; Annoesjka Novak
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study.

Authors:  Li-Chia Chen; Darren M Ashcroft; Rachel A Elliott
Journal:  Pharm World Sci       Date:  2007-06-14

Review 4.  Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members.

Authors:  H L Tan
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

5.  High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open-label Danish study.

Authors:  Karen Schreiber; Matthias Kant; Claudia Pfleger; Henrik Boye Jensen; Ole Oesterberg; Anne Rieper Hald; Frederik K Nielsen; Sune Rubak
Journal:  Patient Prefer Adherence       Date:  2018-06-29       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.